Frontline Brentuximab Vedotin as Monotherapy or in Combination for Older Hodgkin Lymphoma Patients

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2021年 / 19卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：9 / 10
页数：2
相关论文
共 50 条
  • [41] Toxicities of Brentuximab Vedotin in Children and Adolescents with Hodgkin Lymphoma
    Titapiwatanakun, Ruetima
    Batth, Sukhjeet Singh
    Baker, Katherine
    Tcheng, Wendy
    Fernandez, Karen S.
    BLOOD, 2019, 134
  • [42] A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma
    Oak, Eunhye
    Bartlett, Nancy L.
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (06) : 875 - 882
  • [43] The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
    Lai, Catherine
    Kandahari, Adrese Michael
    Ujjani, Chaitra
    BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY, 2019, 9 : 63 - 71
  • [44] Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma
    Chen, Runzhe
    Chen, Baoan
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 1729 - 1733
  • [45] Significance of Brentuximab Vedotin in the Treatment of Hodgkin's Lymphoma
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (04) : 230 - 231
  • [46] Update on the role of brentuximab vedotin in classical Hodgkin lymphoma
    Tomassetti, Sarah
    Herrera, Alex F.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2018, 9 (09) : 261 - 272
  • [47] Brentuximab Vedotin and Pembrolizumab Combination in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Single-Centre Retrospective Analysis
    Massaro, Fulvio
    Meuleman, Nathalie
    Bron, Dominique
    Vercruyssen, Marie
    Maerevoet, Marie
    CANCERS, 2022, 14 (04)
  • [48] Single-agent brentuximab vedotin as frontline therapy for Hodgkin lymphoma patients with severe hepatic impairment: a report of two cases
    Wang, Yupeng
    Wang, Zi
    Wei, Chong
    Zhao, Danqing
    Zhang, Yan
    Wang, Wei
    Zhang, Wei
    Zhou, Daobin
    ANNALS OF HEMATOLOGY, 2023, 102 (10) : 2973 - 2975
  • [49] Single-agent brentuximab vedotin as frontline therapy for Hodgkin lymphoma patients with severe hepatic impairment: a report of two cases
    Yupeng Wang
    Zi Wang
    Chong Wei
    Danqing Zhao
    Yan Zhang
    Wei Wang
    Wei Zhang
    Daobin Zhou
    Annals of Hematology, 2023, 102 : 2973 - 2975
  • [50] Brentuximab vedotin monotherapy is an effective treatment in a frail pediatric patient with Down syndrome and classical Hodgkin lymphoma
    Vonasek, Julia
    Edslev, Pernille Wendtland
    d'Amore, Francesco
    Hasle, Henrik
    PEDIATRIC BLOOD & CANCER, 2020, 67 (02)
12345